After losing Roche as a partner, Blueprint Medicines has sold US commercial rights to RET inhibitor Gavreto to Rigel Pharma in a deal worth up to $117.5 million.

ZHUHAI, Guangdong -- China's commercial space sector is experiencing rapid growth, as several prominent enterprises in the field have recently unveiled ambitious blueprints for future research and ...

Updated on June 22, 2025 - checked for codes. In Girls Frontline 2: Exilium, there are quite a few codes to help you get some additional resources, and if you are eager to check them out, this guide ...